106 related articles for article (PubMed ID: 20133255)
1. Inflammatory breast cancer: novel preoperative therapies.
Overmoyer BA
Clin Breast Cancer; 2010 Feb; 10(1):27-32. PubMed ID: 20133255
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapies in breast cancer.
Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
[TBL] [Abstract][Full Text] [Related]
4. Primary systemic chemotherapy for inflammatory breast cancer.
Sinclair S; Swain SM
Cancer; 2010 Jun; 116(11 Suppl):2821-8. PubMed ID: 20503414
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
6. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.
Van Laere S; Van der Auwera I; Van den Eynden GG; Fox SB; Bianchi F; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2005 Oct; 93(3):237-46. PubMed ID: 16172796
[TBL] [Abstract][Full Text] [Related]
7. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer.
Turpin E; Bièche I; Bertheau P; Plassa LF; Lerebours F; de Roquancourt A; Olivi M; Espié M; Marty M; Lidereau R; Vidaud M; de Thé H
Oncogene; 2002 Oct; 21(49):7593-7. PubMed ID: 12386822
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
Cristofanilli M; Valero V; Buzdar AU; Kau SW; Broglio KR; Gonzalez-Angulo AM; Sneige N; Islam R; Ueno NT; Buchholz TA; Singletary SE; Hortobagyi GN
Cancer; 2007 Oct; 110(7):1436-44. PubMed ID: 17694554
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy in inflammatory breast cancer.
Yamauchi H; Ueno NT
Cancer; 2010 Jun; 116(11 Suppl):2758-9. PubMed ID: 20503407
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
Costa SD; Loibl S; Kaufmann M; Zahm DM; Hilfrich J; Huober J; Eidtmann H; du Bois A; Blohmer JU; Ataseven B; Weiss E; Tesch H; Gerber B; Baumann KH; Thomssen C; Breitbach GP; Ibishi S; Jackisch C; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Jan; 28(1):83-91. PubMed ID: 19901111
[TBL] [Abstract][Full Text] [Related]
13. Biological therapy of breast cancer: recent clinical applications.
Baar J
Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
[TBL] [Abstract][Full Text] [Related]
14. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
[TBL] [Abstract][Full Text] [Related]
15. Case report of bilateral inflammatory breast cancer.
Masannat YA; Peter M; Turton P; Shaaban AM
Eur J Cancer Care (Engl); 2010 Jul; 19(4):558-60. PubMed ID: 19708943
[TBL] [Abstract][Full Text] [Related]
16. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.
van Golen KL; Wu ZF; Qiao XT; Bao LW; Merajver SD
Cancer Res; 2000 Oct; 60(20):5832-8. PubMed ID: 11059780
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Nasser V; Loriod B; Camerlo J; Tagett R; Tarpin C; Houvenaeghel G; Nguyen C; Maraninchi D; Jacquemier J; Houlgatte R; Birnbaum D; Viens P
Cancer Res; 2004 Dec; 64(23):8558-65. PubMed ID: 15574762
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy for locally advanced breast cancer.
Specht J; Gralow JR
Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
[TBL] [Abstract][Full Text] [Related]
19. Update on inflammatory breast cancer.
Lerebours F; Bieche I; Lidereau R
Breast Cancer Res; 2005; 7(2):52-8. PubMed ID: 15743511
[TBL] [Abstract][Full Text] [Related]
20. Persistent E-cadherin expression in inflammatory breast cancer.
Kleer CG; van Golen KL; Braun T; Merajver SD
Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]